Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Scher

Showing results (291-300 of 692) with videos related to

Pageof 70
Sort By:
Cancer Research|December 18, 2003
Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroidsRichard Enmon, Wei-Hong Yang, Ase M Ballangrud, et al.
Arthritis and Rheumatism|September 1, 1983
Leukapheresis in rheumatoid arthritis. Association of clinical improvement with reversal of anergyS M Wahl, R L Wilder, I M Katona, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 22, 2002
The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxinLisa M Butler, Xianbo Zhou, Wei-Sheng Xu, et al.
Clinical Prostate Cancer|October 4, 2005
Second-line chemotherapy for prostate cancer: patient characteristics and survivalKathleen W Beekman, Mark T Fleming, Howard I Scher, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 9, 2021
Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with <sup>18</sup>F-FDG PET Parameters and Associations with Overall Survival After First-Line Abiraterone or Enzalutamide: A Single-Center Retrospective Cohort StudyAndreas G Wibmer, Michael J Morris, Mithat Gonen, et al.
Cancer Immunology, Immunotherapy : CII|February 24, 2005
Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancerSusan F Slovin, Govind Ragupathi, Cristina Musselli, et al.
Prostate Cancer and Prostatic Diseases|December 24, 2002
The microtubule-stabilizing agents epothilones A and B and their desoxy-derivatives induce mitotic arrest and apoptosis in human prostate cancer cellsL Sepp-Lorenzino, A Balog, D-S Su, et al.
British Journal of Cancer|November 1, 1996
Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapyS D Fosså, C Sternberg, H I Scher, et al.
Neurology|February 13, 2003
Patterns of health care utilization for migraine in England and in the United StatesR B Lipton, A I Scher, T J Steiner, et al.
Neurology|February 25, 2005
Cardiovascular risk factors and migraine: the GEM population-based studyA I Scher, G M Terwindt, H S J Picavet, et al.
Pageof 70

Showing results (291-300 of 692) with videos related to

Sort By:
Pageof 70
Cancer Research|December 18, 2003
Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroidsRichard Enmon, Wei-Hong Yang, Ase M Ballangrud, et al.
Arthritis and Rheumatism|September 1, 1983
Leukapheresis in rheumatoid arthritis. Association of clinical improvement with reversal of anergyS M Wahl, R L Wilder, I M Katona, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 22, 2002
The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxinLisa M Butler, Xianbo Zhou, Wei-Sheng Xu, et al.
Clinical Prostate Cancer|October 4, 2005
Second-line chemotherapy for prostate cancer: patient characteristics and survivalKathleen W Beekman, Mark T Fleming, Howard I Scher, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 9, 2021
Quantification of Metastatic Prostate Cancer Whole-Body Tumor Burden with <sup>18</sup>F-FDG PET Parameters and Associations with Overall Survival After First-Line Abiraterone or Enzalutamide: A Single-Center Retrospective Cohort StudyAndreas G Wibmer, Michael J Morris, Mithat Gonen, et al.
Cancer Immunology, Immunotherapy : CII|February 24, 2005
Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancerSusan F Slovin, Govind Ragupathi, Cristina Musselli, et al.
Prostate Cancer and Prostatic Diseases|December 24, 2002
The microtubule-stabilizing agents epothilones A and B and their desoxy-derivatives induce mitotic arrest and apoptosis in human prostate cancer cellsL Sepp-Lorenzino, A Balog, D-S Su, et al.
British Journal of Cancer|November 1, 1996
Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapyS D Fosså, C Sternberg, H I Scher, et al.
Neurology|February 13, 2003
Patterns of health care utilization for migraine in England and in the United StatesR B Lipton, A I Scher, T J Steiner, et al.
Neurology|February 25, 2005
Cardiovascular risk factors and migraine: the GEM population-based studyA I Scher, G M Terwindt, H S J Picavet, et al.
Pageof 70